Harris Emily M, Chamseddine Sarah, Chu Anne, Senkpeil Leetah, Nikiciuk Matthew, Bourdine Aleksandra, Magin Logan, Al-Musa Amer, Woods Brian, Ozdogan Elif, Saker Sarife, van Konijnenburg David P Hoytema, Yee Christina S K, Nelson Ryan W, Lee Pui, Halyabar Olha, Hale Rebecca C, Day-Lewis Megan, Henderson Lauren A, Nguyen Alan A, Elkins Megan, Ohsumi Toshiro K, Gutierrez-Arcelus Maria, Peyper Janique M, Platt Craig D, Grace Rachael F, LaBere Brenna, Chou Janet
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.
Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
medRxiv. 2025 Jan 27:2024.02.25.24303331. doi: 10.1101/2024.02.25.24303331.
Limited clinical tools exist for characterizing primary immune regulatory disorders (PIRD), which are often diagnoses of exclusion. Increased CD4CXCR5PD1 circulating T follicular helper (cTfh) cell percentages have been identified as a marker of active disease in some, but not all, autoimmune disorders.
To develop a diagnostic approach that combines measurements of cellular and serologic autoimmunity.
We recruited 71 controls and 101 pediatric patients with PIRD with autoimmunity. Flow cytometry was used to measure CD4CXCR5 T cells expressing the chemokine receptors CXCR3 and/or CCR6. IgG and IgA autoantibodies were quantified in 56 patients and 20 controls using a microarray featuring 1616 full-length, conformationally intact protein antigens. The 97.5 percentile in the controls serves as the upper limit of normal for percentages of cTfh cells, CD4CXCR5 T cells expressing CXCR3 and/or CCR6, and autoantibody intensity and number.
We found that 27.7% of patients had increased percentages of CD4CXCR5PD1 cTfh cells and 42.5% had increased percentages of CD4CXCR5 cells expressing CXCR3 and/or CCR6. Patients had significantly more diverse IgG and IgA autoantibodies than controls and 37.5% had increased numbers of high-titer autoantibodies. Integrating measurements of cTfh cells, CD4CXCR5 T cells with CXCR3 and/or CCR6, and numbers of high-titer autoantibodies had 71.4% sensitivity (95% CI: 0.5852 - 0.8158) and 85% specificity (95% CI: 0.6396 - 0.9476) for patients with PIRD compared to controls.
By integrating CD4 T cell phenotyping and total burden of autoantibodies, this approach provides additional tools for the diagnosis of PIRD lacking clinical diagnostic criteria.
用于表征原发性免疫调节障碍(PIRD)的临床工具有限,PIRD通常是排除性诊断。循环T滤泡辅助细胞(cTfh)中CD4⁺CXCR5⁺PD-1⁺细胞百分比升高已被确定为某些(但并非所有)自身免疫性疾病中活动性疾病的标志物。
开发一种结合细胞和血清自身免疫测量的诊断方法。
我们招募了71名对照者和101名患有自身免疫性PIRD的儿科患者。采用流式细胞术检测表达趋化因子受体CXCR3和/或CCR6的CD4⁺CXCR5⁺T细胞。使用包含1616种全长、构象完整的蛋白质抗原的微阵列,对56名患者和20名对照者的IgG和IgA自身抗体进行定量。对照者中第97.5百分位数用作cTfh细胞百分比、表达CXCR3和/或CCR6的CD4⁺CXCR5⁺T细胞百分比以及自身抗体强度和数量的正常上限。
我们发现,27.7%的患者CD4⁺CXCR5⁺PD-1⁺cTfh细胞百分比升高,42.5%的患者表达CXCR3和/或CCR6的CD4⁺CXCR5⁺细胞百分比升高。患者的IgG和IgA自身抗体比对照者明显更多样化,37.5%的患者高滴度自身抗体数量增加。综合测量cTfh细胞、表达CXCR3和/或CCR6的CD4⁺CXCR5⁺T细胞以及高滴度自身抗体数量,与对照者相比,对PIRD患者的敏感性为71.4%(95%CI:0.